Organ Care System safe and feasible for lung transplant patients

The Lancet has published the initial series of successful lung transplants demonstrating the feasibility and safety of using the Organ Care System™ (OCS™) Lung technology, at Hannover Medical School and Puerta de Hierro Hospital Madrid.   

A study published in the October 10^th edition of The Lancet reports on the first in-man clinical experience with the OCS Lung technology. These cases were conducted in two leading lung transplant centers in Germany and Spain.  Representing a full spectrum of donor and recipient risk factors/indications for lung transplantation, these cases evaluate the feasibility and safety of the OCS technology.  All lungs were successfully preserved on the OCS system and transplanted with excellent results. This study was the foundation to initiate the ongoing international prospective randomized INSPIRE Trial to evaluate the effectiveness of the OCS Lung device.

"Our early clinical data supports the use of the OCS Lung. We show good outcomes of lung transplantation following preservation on OCS Lung in a high-risk recipient population," said Dr. Gregor Warnecke at the Hannover Medical School in Germany. "The full potential of this technology will be exemplified in the data resulting from the ongoing INSPIRE Trial and we are enthusiastic to move this important trial forward."

"We are excited by The Lancet publication and we look forward to continuing our global collaboration with leading lung transplant centers to complete and report the results from the INSPIRE Trial," said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc.

SOURCE TransMedics, Inc.